The current toolbox for APOBEC drug discovery

Trends Pharmacol Sci. 2022 May;43(5):362-377. doi: 10.1016/j.tips.2022.02.007.

Abstract

Mutational processes driving genome evolution and heterogeneity contribute to immune evasion and therapy resistance in viral infections and cancer. APOBEC3 (A3) enzymes promote such mutations by catalyzing the deamination of cytosines to uracils in single-stranded DNA. Chemical inhibition of A3 enzymes may yield an antimutation therapeutic strategy to improve the durability of current drug therapies that are prone to resistance mutations. A3 small-molecule drug discovery efforts to date have been restricted to a single high-throughput biochemical activity assay; however, the arsenal of discovery assays has significantly expanded in recent years. The assays used to study A3 enzymes are reviewed here with an eye towards their potential for small-molecule discovery efforts.

Keywords: APOBEC; DNA deaminase inhibitors; chemical probes; drug discovery; screening.

Publication types

  • Review
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytidine Deaminase* / genetics
  • Drug Discovery*
  • Humans
  • Mutation

Substances

  • Cytidine Deaminase